UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.06 +0.06 (+0.08%) GOLD FUTURES
2,313.40 +2.40 (+0.10%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,052.95 +738.76 (+1.60%)
Blueprint Medicines Corporation (BPMC)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 94.86 |
| Open | 104.20 |
| Bid | 106.66 x 700 |
| Ask | 107.03 x 300 |
| Day's range | 100.90 - 110.16 |
| 52-week range | 43.89 - 110.16 |
| Volume | |
| Avg. volume | 813,908 |
| Market cap | 6.721B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.37 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 98.00 |
- GuruFocus.com
Blueprint Medicines Corp Reports Q1 2024 Earnings, Surpasses Revenue Estimates and Raises ...
Detailed Analysis of Financial Performance and Strategic Updates
ZacksBlueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.51% and 16.40%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireBlueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2024, and provided updated financial guidance.
© 2024 Yahoo. All rights reserved.